An age-independent gene signature for monitoring acute rejection in kidney transplantation.
Abstract
Acute rejection (AR) remains a significant problem that negatively impacts long-term
renal allograft survival. Numerous therapies are used to prevent AR that differ by
center and recipient age. This variability confounds diagnostic methods. Methods:
To develop an age-independent gene signature for AR effective across a broad array
of immunosuppressive regimens, we compiled kidney transplant biopsy (n=1091) and peripheral
blood (n=392) gene expression profiles from 12 independent public datasets. After
removing genes differentially expressed in pediatric and adult patients, we compared
gene expression profiles from biopsy and peripheral blood samples of patients with
AR to those who were stable (STA), using Mann-Whitney U Tests with validation in independent
testing datasets. We confirmed this signature in pediatric and adult patients (42
AR and 47 STA) from our institutional biorepository. Results: We identified a novel
age-independent gene network that identified AR from both kidney and blood samples.
We developed a 90-probe set signature targeting 76 genes that differentiated AR from
STA and found an 8 gene subset (DIP2C, ENOSF1, FBXO21, KCTD6, PDXDC1, REXO2, HLA-E,
and RAB31) that was associated with AR. Conclusion: We used publicly available datasets
to create a gene signature of AR that identified AR irrespective of immunosuppression
regimen or recipient age. This study highlights a novel model to screen and validate
biomarkers across multiple treatment regimens.
Type
Journal articlePermalink
https://hdl.handle.net/10161/21157Published Version (Please cite this version)
10.7150/thno.42110Publication Info
Shaw, Brian I; Cheng, Daniel K; Acharya, Chaitanya R; Ettenger, Robert B; Lyerly,
Herbert Kim; Cheng, Qing; ... Chambers, Eileen T (2020). An age-independent gene signature for monitoring acute rejection in kidney transplantation.
Theranostics, 10(15). pp. 6977-6986. 10.7150/thno.42110. Retrieved from https://hdl.handle.net/10161/21157.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Eileen Tsai Chambers
Associate Professor of Pediatrics
Qing Cheng
Associate Professor in Surgery
My research has been focusing on the development of methodologies and strategies to
address the general question of human cancer heterogeneity and complexity, recognizing
that clinical outcomes reflect a combination of contribution from the actual tumor
but also the environment in which the tumor resides. By understanding who is at risk
for recurrence, who is likely to respond to a given agent or regimen, and who is likely
to exhibit an adverse event associated with a particular therapy, it will
Allan Douglas Kirk
David C. Sabiston, Jr. Distinguished Professor of Surgery
I am a surgeon with interest in immune management of transplant recipients. I am particularly
interested in therapies that influence T cell costimulation pathways and adjuvant
therapies that facilitate costimulation blockade to prevent the rejection of transplanted
organs without undue suppression of protective immunity. I am also interested in understanding
how injury, such as that occurring during trauma or in elective surgery, influences
immune responses and subsequent healing following injur
Herbert Kim Lyerly
George Barth Geller Distinguished Professor of Immunology
Brian Shaw
House Staff
Alphabetical list of authors with Scholars@Duke profiles.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info